Roller-Compacted Granules: Dry Granulation Constraints for Moisture-Sensitive Ampoule API

Transfer of an ampoule pharma grade API into immediate-release tablets via dry granulation is selected when the API exhibits hydrolytic degradation at moisture levels above 1.0–2.0 wt%. Powder feed with D10 8 µm, D50 45 µm, and D90 160 µm combined with bulk density of 0.28–0.38 g/cm³ typically produces a Hausner ratio above 1.40, which is unsuitable for direct compression on a high-speed rotary press. Pre-blending is performed in a 600 L bin blender at 8–10 rpm for 15 min with microcrystalline cellulose PH102, lactose monohydrate 200 mesh, and croscarmellose sodium. The resulting blend is compacted on an Alexanderwerk WP 120 roller compactor with roll force 12–18 kN/cm, roll speed 5–7 rpm, and gap 1.5–2.0 mm. Ribbon density is held between 1.20–1.40 g/cm³; lower density yields excessive fines and higher density causes loss of tablet compressibility. The ribbons are screened through 0.8 mm and 1.25 mm integrated oscillating granulators. Granule fractions below 0.180 mm are recycled at not more than 25 wt% to avoid densification drift. Lubrication with sodium stearyl fumarate at 0.5–1.0 wt% is completed in 3–5 min. Tablets are compressed on a Korsch XL 800 rotary press with compression force 8–18 kN, pre-compression force 2–4 kN, and turret speed 30–60 rpm. Target tablet hardness is 50–100 N, friability not more than 0.8 wt% by Ph. Eur. 2.9.7, and disintegration time not more than 15 min in water at 37 °C by USP <701>. Published data for roller-compacted products of this specific ampoule-grade API may be limited; in such cases, roll force and ribbon density must be mapped on the production machine because bench-scale powder rheology does not reliably predict compactability at high throughput.

What Limits Blend Uniformity When Ampoule API Is Filled into Hard Gelatin Capsules?

Capsule filling of a low-dose ampoule pharma grade API at 0.5–10 mg per capsule is governed by particle-size distribution, cohesive forces, and the risk of de-mixing in the hopper. A pre-mix with bulk lactose monohydrate 100 mesh is passed through a 0.5 mm conical screen to break API agglomerates. The API is then diluted geometrically in a 200 L diffusion mixer at 10–12 rpm for 20 min. Fill powder specifications include Hausner ratio 1.25–1.45, Carr index 20–30%, and moisture not more than 1.5 wt% to prevent sticking to dosing disks. On a Bosch GKF 2600 capsule filler, dosing station pins or disks are selected between 16–25 mm diameter depending on target fill weight 120–350 mg. Machine speed is restricted to 50–70% of rated capacity when bulk density falls below 0.40 g/cm³. Content uniformity is evaluated according to USP <905> with acceptance value not more than 15.0. Dissolution testing uses USP <711> Apparatus 2 at 50 rpm in 900 mL of 0.1 N HCl for immediate-release capsules, with sampling at 10 min, 20 min, 30 min, and 45 min. When magnesium stearate is used at 0.25–0.50 wt%, blending must not exceed 5 min because over-lubrication produces hydrophobic film on lactose and API and can reduce dissolution below Q 80% at 30 min. Gelatin capsule shell moisture of 13–16 wt% is acceptable for non-hygroscopic fill powders; lower shell moisture increases brittleness during separation and higher shell moisture can soften and deform under 35 °C processing conditions.

In sachet-scale paediatric oral granules, the ampoule pharma grade API is incorporated at dose strengths from 2.5 mg to 20 mg per sachet using wet granulation, because direct powder dosing is unsafe and uniformity risk is high. A binder solution of PVP K30 at 3.0–5.0 wt% solids in purified water is added at 8–15 wt% of the dry powder charge in a Lödige MGT-70 high-shear granulator. Impeller speed is ramped from 100 rpm to 250 rpm with chopper speed 1,500–3,000 rpm; endpoint is declared when measured torque reaches 30–45 Nm or power draw rises 15–20% above dry mixing baseline. Wet mass is discharged through a 1.0 mm sieve and dried in a Glatt GPCG 3.1 fluid-bed dryer with inlet air temperature 55–65 °C, product temperature 35–42 °C, and air volume 250–400 m³/h. Final loss on drying is held at 1.0–1.5 wt% by Ph. Eur. 2.2.32. Dried granules are sieved through 0.8 mm and 1.25 mm; fines below 0.180 mm should not exceed 15 wt% to maintain flow and reduce dust generation during sachet filling on a Volpak horizontal form-fill-seal line. Sachet fill weight tolerance is ±5% across 30–60 sachets/min. Dissolution uses USP <711> Apparatus 2 at 50 rpm in 500 mL of 0.1 N HCl; a pH shift to 6.8 phosphate buffer after 30 min detects pH-dependent solubility gaps in children with elevated gastric pH. The API concentration requires HPLC assay according to a validated stability-indicating method with LOQ not more than 0.05 µg/mL. The granulation is incompatible with unmodified starch as the sole binder under high shear because granule strength collapses during drying when moisture content drops below 1.0 wt%, leading to segregation in the hopper.

Terminal Sterilisation Feasibility for Ampoule-Packed API in Aqueous Injection

For injectable ampoule finishing, the ampoule pharma grade API is dissolved in Water for Injection at 5–50 mg/mL and pH is adjusted to 4.0–7.0 with 0.1 N hydrochloric acid or sodium hydroxide under nitrogen overlay. Osmolality is adjusted with sodium chloride or dextrose to 285–310 mOsm/kg as measured by freezing point depression. The solution is sparged with sterile-filtered nitrogen to maintain dissolved oxygen below 0.5 mg/L when the API contains oxidation-prone phenol or thioether functionalities. Filtration is sequenced through 0.45 µm and 0.22 µm PVDF cartridge filters with minimum bubble point 3.0 bar for the 0.22 µm membrane. Filling is performed on a Groninger RFN 2010 ampoule line into borosilicate glass ampoules conforming to Ph. Eur. 3.2.1; fill volumes are 1.0 mL, 2.0 mL, 5.0 mL, and 10.0 mL with overfill volume determined by USP <1> or Ph. Eur. 2.9.17. Tip-sealing uses oxygen/natural gas flame at 1,200–1,600 °C; improper flame temperature produces tip leakage, while excessive temperature can recrystallise API at the constriction. Residual solvent and elemental impurity limits follow ICH Q3C(R8) and ICH Q3D(R2). For heat-stable formulations, terminal sterilisation at 121 °C for 15 min is applied after sealing; for heat-labile formulations, aseptic filtration and filling under EU GMP Annex 1 grade A conditions is required. The release test matrix is presented in Table 1.

When the finished dosage form is an oral suspension, the ampoule pharma grade API is dispersed in an aqueous vehicle containing microcrystalline cellulose/carboxymethylcellulose sodium at 1.0–2.0 wt%, polysorbate 80 at 0.1–0.5 wt%, sorbitol solution 20–30 wt%, sodium benzoate 0.1–0.2 wt%, and pH adjusted to 4.0–6.0 with citric acid. High-shear rotor-stator homogenization at 3,000–6,000 rpm for 15–30 min reduces agglomerates to D90 not more than 30 µm; the suspension is cooled to 20–25 °C and transferred through a 0.5 mm in-line strainer before filling into amber PET bottles. Viscosity is controlled between 200–500 mPa·s at 25 °C on a Brookfield DV2T spindle LV3 at 60 rpm to balance pourability and sedimentation stability. Sedimentation volume after 24 h should be not less than 0.90, and redispersibility should require not more than 30 s of manual shaking after 7 days. Microbial limits follow USP <61> for total aerobic microbial count and USP <62> for specified pathogens. The suspension should not be combined with aluminium-containing antacids because pH shifts above 6.5 can alter the ionisation state of the API and reduce chemical stability; this limitation must be stated in the product monograph.

When a 24-Hour Release Profile Demands High-Viscosity Hydroxypropyl Methylcellulose Matrices

In controlled-release tablet development, the ampoule pharma grade API is embedded in a swollen matrix rather than used as a free-flowing powder. Direct compression is performed after dry blending the API with hypromellose K4M at 20–40 wt%, hypromellose K100M at 10–20 wt%, microcrystalline cellulose 20–30 wt%, and colloidal silicon dioxide 0.5–1.0 wt%. The blend is lubricated with magnesium stearate 0.5–1.0 wt% in a low-shear V-blender for 3 min. Tablets of 250–500 mg weight are compressed to hardness 120–180 N on a rotary press with 10–15 kN compression force. Matrix integrity is assessed by measuring gel-layer thickness after 2 h in pH 6.8 phosphate buffer; premature erosion indicates insufficient polymer entanglement at the tablet surface. Dissolution must cover 0–24 h sampling in USP <711> Apparatus 1 or 2 with sinkers; typical release markers are Q 20–40% at 2 h, Q 50–70% at 8 h, and Q 80–100% at 24 h. Process bottleneck occurs when API particle D90 exceeds 180 µm because large crystals create local depressions in the gel layer and release variability. Scaling from lab to production requires mapping compression force against porosity; porosity below 15% can retard drug release beyond acceptable limits, while porosity above 25% can cause dose dumping after exposure to 0.1 N HCl for 2 h.